Cargando…
Antirheumatic drugs and reproduction in women and men with chronic arthritis
The impact of rheumatic disease on fertility and reproduction can be remarkable. Many disease-related factors can influence patients’ sexual functioning, perturb fertility and limit family planning. Antirheumatic pharmacological treatment can also have a crucial role in this field. Proper counsellin...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632146/ https://www.ncbi.nlm.nih.gov/pubmed/26557371 http://dx.doi.org/10.1136/rmdopen-2015-000048 |
_version_ | 1782398969954959360 |
---|---|
author | Bazzani, Chiara Andreoli, Laura Agosti, Michele Nalli, Cecilia Tincani, Angela |
author_facet | Bazzani, Chiara Andreoli, Laura Agosti, Michele Nalli, Cecilia Tincani, Angela |
author_sort | Bazzani, Chiara |
collection | PubMed |
description | The impact of rheumatic disease on fertility and reproduction can be remarkable. Many disease-related factors can influence patients’ sexual functioning, perturb fertility and limit family planning. Antirheumatic pharmacological treatment can also have a crucial role in this field. Proper counselling, preferably provided by a multidisciplinary team of rheumatologists, obstetricians, gynaecologists and neonatologists, is recommended for patients taking antirheumatic drugs, not only at the beginning, but also during the course of treatment. Paternal exposure to antirheumatic drugs was not found to be specifically associated with congenital malformation and adverse pregnancy outcome, therefore discontinuation of these drugs while planning for conception should be weighed against the risk of disease flare. Drugs in Food and Drug Administration (FDA) category ‘X’ should be withdrawn in a timely manner in women who desire a pregnancy. Meanwhile, disease control can be achieved with anti-tumour necrosis factor (TNF)-α agents, which are not teratogenic drugs. If maternal disease control is permissive, they can be stopped as soon as the pregnancy test turns positive and be resumed during pregnancy in case of a flare. |
format | Online Article Text |
id | pubmed-4632146 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-46321462015-11-09 Antirheumatic drugs and reproduction in women and men with chronic arthritis Bazzani, Chiara Andreoli, Laura Agosti, Michele Nalli, Cecilia Tincani, Angela RMD Open Proceedings from OsteoRheumatology 2014 The impact of rheumatic disease on fertility and reproduction can be remarkable. Many disease-related factors can influence patients’ sexual functioning, perturb fertility and limit family planning. Antirheumatic pharmacological treatment can also have a crucial role in this field. Proper counselling, preferably provided by a multidisciplinary team of rheumatologists, obstetricians, gynaecologists and neonatologists, is recommended for patients taking antirheumatic drugs, not only at the beginning, but also during the course of treatment. Paternal exposure to antirheumatic drugs was not found to be specifically associated with congenital malformation and adverse pregnancy outcome, therefore discontinuation of these drugs while planning for conception should be weighed against the risk of disease flare. Drugs in Food and Drug Administration (FDA) category ‘X’ should be withdrawn in a timely manner in women who desire a pregnancy. Meanwhile, disease control can be achieved with anti-tumour necrosis factor (TNF)-α agents, which are not teratogenic drugs. If maternal disease control is permissive, they can be stopped as soon as the pregnancy test turns positive and be resumed during pregnancy in case of a flare. BMJ Publishing Group 2015-08-15 /pmc/articles/PMC4632146/ /pubmed/26557371 http://dx.doi.org/10.1136/rmdopen-2015-000048 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
spellingShingle | Proceedings from OsteoRheumatology 2014 Bazzani, Chiara Andreoli, Laura Agosti, Michele Nalli, Cecilia Tincani, Angela Antirheumatic drugs and reproduction in women and men with chronic arthritis |
title | Antirheumatic drugs and reproduction in women and men with chronic arthritis |
title_full | Antirheumatic drugs and reproduction in women and men with chronic arthritis |
title_fullStr | Antirheumatic drugs and reproduction in women and men with chronic arthritis |
title_full_unstemmed | Antirheumatic drugs and reproduction in women and men with chronic arthritis |
title_short | Antirheumatic drugs and reproduction in women and men with chronic arthritis |
title_sort | antirheumatic drugs and reproduction in women and men with chronic arthritis |
topic | Proceedings from OsteoRheumatology 2014 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4632146/ https://www.ncbi.nlm.nih.gov/pubmed/26557371 http://dx.doi.org/10.1136/rmdopen-2015-000048 |
work_keys_str_mv | AT bazzanichiara antirheumaticdrugsandreproductioninwomenandmenwithchronicarthritis AT andreolilaura antirheumaticdrugsandreproductioninwomenandmenwithchronicarthritis AT agostimichele antirheumaticdrugsandreproductioninwomenandmenwithchronicarthritis AT nallicecilia antirheumaticdrugsandreproductioninwomenandmenwithchronicarthritis AT tincaniangela antirheumaticdrugsandreproductioninwomenandmenwithchronicarthritis |